Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...
Please provide your email address to receive an email when new articles are posted on . Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of ...
LONDON — A new analysis of the IMPROVE-IT trial indicates that the nonstatin, cholesterol-lowering drug ezetimibe (Zetia, Merck) is of specific benefit in patients with acute coronary syndrome who ...
A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...
HealthDay News— For patients with hypercholesterolemia, simvastatin is superior to ezetimibe for producing lymphocyte-suppression and systemic anti-inflammatory and endothelial protective effects, ...
(HealthDay)—Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...
What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or 2 alone or in combination with other ...
The US Food and Drug Administration has declined to extend the indication for the cholesterol-lowering drug ezetimibe to include cardiovascular event reduction, the manufacturer has announced. Merck ...
Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin ...
A US Food and Drug Administration (FDA) advisory committee voted yesterday against approving a claim that adding ezetimibe, marketed as Zetia by Merck/Schering-Plough, to statin therapy reduces the ...
(HealthDay News) — Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback